Search

Your search keyword '"MESH: Paraffin Embedding"' showing total 7 results
Start Over Descriptor "MESH: Paraffin Embedding"
7 results on '"MESH: Paraffin Embedding"'

1. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data

Author

Cécile Rouzier, Jean Amiel, Jean-François Michiels, Laure Valério, Juliette Haudebourg, Florence Pedeutour, Xavier Carpentier, Laboratory of Solid Tumors Genetics, Nice University Hospital, Institut de signalisation, biologie du développement et cancer (ISBDC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Laboratoire d'Anatomo-Pathologie, Hôpital Pasteur [Nice] (CHU), Laboratoire d'Urologie, Department of Public Health, and Hôpital l'Archet

Subjects
Male, Cancer Research, Oncogene Proteins, Fusion, Oncogene Proteins, MESH: Paraffin Embedding, Chromosomal translocation, MESH: Formaldehyde, law.invention, Fusion gene, MESH: Aged, 80 and over, 0302 clinical medicine, law, Prostate, MESH: Reverse Transcriptase Polymerase Chain Reaction, MESH: Fixatives, MESH: Serine Endopeptidases, Polymerase chain reaction, MESH: Aged, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, Paraffin Embedding, Reverse Transcriptase Polymerase Chain Reaction, Serine Endopeptidases, MESH: Transcription Factors, Middle Aged, 3. Good health, DNA-Binding Proteins, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Adenocarcinoma, Adenovirus E1A Proteins, PCA3, MESH: Proto-Oncogene Proteins c-ets, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Fixatives, 03 medical and health sciences, Antigen, Formaldehyde, Proto-Oncogene Proteins, Genetics, medicine, Humans, Molecular Biology, Aged, Retrospective Studies, 030304 developmental biology, MESH: Humans, Proto-Oncogene Proteins c-ets, MESH: Adenocarcinoma, Prostatic Neoplasms, MESH: Retrospective Studies, medicine.disease, MESH: Adenovirus E1A Proteins, MESH: Male, MESH: Proto-Oncogene Proteins, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, MESH: Prostatic Neoplasms, Immunology, Cancer research, Feasibility Studies, MESH: Feasibility Studies, MESH: DNA-Binding Proteins, MESH: Oncogene Proteins, Fusion, Transcription Factors
Abstract

The recent identification of fusion genes involving ETS family members in human prostate adenocarcinoma has confirmed the hypothesis that recurrent specific aberrations such as fusion genes may be as frequent in epithelial tumors as they are in leukemias and sarcomas. However, reciprocal translocations with fusion genes are often not detectable in carcinomas by conventional karyotyping because of additional complex chromosomal abnormalities. We retrospectively analyzed a large series of formalin-fixed, paraffin-embedded samples including 55 prostate carcinomas and 11 benign prostate tumors. We identified the fusion gene TMPRSS2-ERG by reverse-transcriptase polymerase chain reaction (RT-PCR) in 40/55 carcinomas (72%). Our study demonstrates that the detection of ETS fusion gene by RT-PCR is feasible on formalin-fixed and paraffin-embedded samples. No significant association between the presence of the fusion gene and any clinical feature, such as preoperative serum prostate-specific antigen (PSA) level (PSA>20 or PSA< or =20), pTNM stage including capsule invasion, seminal vesicle invasion, and lymph nodes metastases, or recurrence was observed in our series.

Published
2008
Full Text
View/download PDF

2. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies

Author

Ram-Wolff, Caroline, Martin-Garcia, Nadine, Bensussan, Armand, Bagot, Martine, Ortonne, Nicolas, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
MESH: Immunophenotyping, MESH: Antigens, CD3, MESH: Dermatitis, Exfoliative, MESH: Paraffin Embedding, MESH: beta Catenin, ß-catenin, MESH: Phenotype, JunB, MESH: Biopsy, MESH: Aged, 80 and over, MESH: Skin, MESH: Diagnosis, Differential, hemic and lymphatic diseases, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Dermatitis, MESH: Aged, MESH: Psoriasis, MESH: Humans, MESH: Middle Aged, integumentary system, MESH: Proto-Oncogene Proteins c-jun, erythroderma, MESH: Skin Neoplasms, MESH: Adult, MESH: Retrospective Studies, MESH: Male, MESH: Predictive Value of Tests, MESH: France, MESH: Eczema, Sézary syndrome, CD30, MESH: Sezary Syndrome, histopathology, MESH: Drug Eruptions, MESH: Lymphocytes, MESH: Antigens, CD8, MESH: Female
Abstract

International audience; Erythroderma may be secondary to a cutaneous T-cell lymphoma (CTCL) and various other erythrodermic inflammatory dermatoses (EID), and their histopathologic distinction is often difficult. The aim of this study was to determine if morphological parameters, namely: the presence of b-catenin, and JunB (previously shown to be expressed by CTCL cells), the epidermal CD8:CD3 ratio, and CD30 expression may help in the histopathologic diagnosis of erythroderma, especially in differentiating CTCL and EID. We retrospectively reviewed a series of 47 skin biopsies from patients with erythroderma (18 CTCL and 29 EID). The diagnosis of each case was established using clinical, biological and histopathologic data. After a blind assessment of the hematoxylin--eosin--safran stained slides, a correct diagnosis of the underlying cause of erythroderma was made only in 31% of cases. A correct differential diagnosis between lymphoma and EID was done with certainty in 57% of cases. Various morphologic and phenotypic parameters were then recorded and we compared their frequency in the CTCL versus the EID group. With the exception of atypical lymphocytes, the moderate to high density of dermal infiltrates and Pautrier microabcesses, only found in CTCL, no morphologic parameter was found to be specific of CTCL, although single lymphocytes epidermotropism, telangiectasias, and slight lymphocytic dermal infiltrate were significantly more frequent in EID. A low (

Published
2010
Full Text
View/download PDF

3. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies.: Histopathological diagnosis of erythroderma

Author

Ram-Wolff, Caroline, Martin-Garcia, Nadine, Bensussan, Armand, Bagot, Martine, Ortonne, Nicolas, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Immunologie, dermatologie, oncologie, Oncodermatologie, immunologie et cellules souches cutanées (IDO (U976 / UMR_S 976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de dermatologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Guellaen, Georges

Subjects
MESH: Immunophenotyping, MESH: Antigens, CD3, MESH: Dermatitis, Exfoliative, MESH: Paraffin Embedding, MESH: beta Catenin, ß-catenin, MESH: Phenotype, JunB, MESH: Biopsy, MESH: Aged, 80 and over, MESH: Skin, MESH: Diagnosis, Differential, hemic and lymphatic diseases, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Dermatitis, MESH: Aged, MESH: Psoriasis, MESH: Humans, MESH: Middle Aged, integumentary system, MESH: Proto-Oncogene Proteins c-jun, erythroderma, MESH: Skin Neoplasms, MESH: Adult, MESH: Retrospective Studies, MESH: Male, MESH: Predictive Value of Tests, MESH: France, MESH: Eczema, Sézary syndrome, CD30, MESH: Sezary Syndrome, histopathology, MESH: Drug Eruptions, MESH: Lymphocytes, MESH: Antigens, CD8, MESH: Female
Abstract

International audience; Erythroderma may be secondary to a cutaneous T-cell lymphoma (CTCL) and various other erythrodermic inflammatory dermatoses (EID), and their histopathologic distinction is often difficult. The aim of this study was to determine if morphological parameters, namely: the presence of b-catenin, and JunB (previously shown to be expressed by CTCL cells), the epidermal CD8:CD3 ratio, and CD30 expression may help in the histopathologic diagnosis of erythroderma, especially in differentiating CTCL and EID. We retrospectively reviewed a series of 47 skin biopsies from patients with erythroderma (18 CTCL and 29 EID). The diagnosis of each case was established using clinical, biological and histopathologic data. After a blind assessment of the hematoxylin--eosin--safran stained slides, a correct diagnosis of the underlying cause of erythroderma was made only in 31% of cases. A correct differential diagnosis between lymphoma and EID was done with certainty in 57% of cases. Various morphologic and phenotypic parameters were then recorded and we compared their frequency in the CTCL versus the EID group. With the exception of atypical lymphocytes, the moderate to high density of dermal infiltrates and Pautrier microabcesses, only found in CTCL, no morphologic parameter was found to be specific of CTCL, although single lymphocytes epidermotropism, telangiectasias, and slight lymphocytic dermal infiltrate were significantly more frequent in EID. A low (

Published
2010
Full Text
View/download PDF

4. [Management of muscle and nerve biopsies: expert guidelines from two French professional societies, Société française de myologie et de l'Association française contre les myopathies] : Prise en charge des biopsies musculaires et nerveuses. Recommandations formalisées d'experts sous l'égide de la Société française de neuropathologie, de la Société française de myologie et de l'Association française contre les myopathies

Author

Uro-Soste, E., Fernandez, C., Authier, François-Jérôme, Bassez, G., Butori, C., Chapon, F., Delisle, M.-B., Dubourg, O., Feasson, L., Gherardi, R., Lacroix, C., Laquerriere, A., Letournel, F., Magy, Laurent, Maisonobe, T., Marcorelles, Pascale, Maurage, C.-A., Mezin, P., Mussini, J.-M., Penisson-Besnier, I., Romero, N.-B., Streichenberger, N., Vallat, Jean-Michel, Viennet, G., Vital, A., Voit, T., Boucharef, W., Figarella-Branger, D., Renseigné, Non, Service d'anatomie pathologique et histologie-cytologie [Rangueil], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Centre de référence des maladies rares neuromusculaires Aquitaine-Grand Sud Ouest, Service d'anatomie pathologique et de neurophatologie, Assistance Publique - Hôpitaux de Marseille (APHM)-CHU Marseille, Centre de référence des maladies rares neuromusculaires, INSERM U955, équipe 10, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre de référence des maladies rares neuromusculaires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de pathologie clinique et expérimentale, Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de compétences pathologies neuromusculaires [CHU Caen], Thérapie des maladies du muscle strié, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de physiologie clinique, unité de myologie, CHU Saint-Etienne, Centre de référence des neuropathies amyloïdes et autres neuropathies rares, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Laboratoire de neuropathologie, Service d'Anatomie et Cytologie Pathologique [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de Pathologie Cellulaire et Tissulaire, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Laboratoire de Neurobiologie et Neuropathologie, Service de Neurologie [CHU Limoges], CHU Limoges, Biomolécules Thérapies anti-tumorales (EA4021), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Centre de référence national neuropathies périphériques rares [CHU Limoges], Service d'Anatomomie pathologique, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre de compétence des maladies rares neuromusculaires, Service d'anatomie pathologique, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département d'anatomie et cythologie pathologique, CHU Grenoble-Hôpital Michallon, CHU Grenoble, Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de neurologie [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), Service de pathologie et neuropatologie, Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Estrogènes, Expression génique et pathologies du Système Nerveux Central - UFC (E2SNC / ESTROGENES), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Bordeaux [Bordeaux], Service des actions médicales, paramédicales et psychologiques, Association Française contre les Myopathies, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], IMRB - 'Biologie du système neuromusculaire' [Créteil] (U955 Inserm - UPEC), École nationale vétérinaire - Alfort (ENVA)-Institut Mondor de Recherche Biomédicale (IMRB), Centre de référence des maladies rares neuromusculaires [CHU Pitié-Salpétriêre], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Reference des Maladies Neuromusculaires - Atlantique Occitanie Caraïbe (CRMN - AOC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)

Subjects
MESH: Muscle, Skeletal, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, MESH: Paraffin Embedding, MESH: Immunohistochemistry, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Peripheral Nerves, MESH: Biopsy, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], MESH: Fixatives, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Glutaral, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010
Full Text
View/download PDF

5. Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient

Author

Véronique Hofman, Michele Baumann, Nicolas Venissac, Dea Garcia-Hermoso, Paul Hofman, Martine Gari-Toussaint, Bernard Padovani, Abdelmajid Dhouibi, Catherine Butori, Gieri Cathomas, Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Human Biobank, Department of Radiology, Laboratory of Mycology, Archet II Hospital, Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Laboratory for Molecular and Infectious Disease Pathology, Cantonal Institute for Pathology, Department of Thoracic Surgery, and Institut Pasteur [Paris] (IP)

Subjects
Male, MESH: Fatal Outcome, Pathology, Tissue Fixation, MESH: Paraffin Embedding, Case Report, MESH: Formaldehyde, Aspergillosis, Polymerase Chain Reaction, MESH: Kidney Transplantation, Aspergillus fumigatus, Fatal Outcome, 0302 clinical medicine, MESH: Rhizopus, MESH: Immunocompromised Host, MESH: Fixatives, Lung, MESH: Aged, Invasive Pulmonary Aspergillosis, 0303 health sciences, Paraffin Embedding, biology, General Medicine, MESH: Predictive Value of Tests, 3. Good health, MESH: Staining and Labeling, medicine.anatomical_structure, 030220 oncology & carcinogenesis, MESH: Immunosuppressive Agents, MESH: Aspergillus fumigatus, MESH: Tomography, X-Ray Computed, Bronchoalveolar Lavage Fluid, Immunosuppressive Agents, Rhizopus, medicine.drug, lcsh:RB1-214, Mucorales, MESH: Pneumonia, MESH: Invasive Pulmonary Aspergillosis, Rhizopus microsporus, medicine.medical_specialty, Histology, Pathology and Forensic Medicine, Fixatives, Immunocompromised Host, Necrosis, 03 medical and health sciences, Predictive Value of Tests, Formaldehyde, medicine, lcsh:Pathology, Humans, Mucormycosis, MESH: Lung, MESH: Mucormycosis, Aged, MESH: Necrosis, Voriconazole, MESH: Humans, Staining and Labeling, MESH: Bronchoalveolar Lavage Fluid, 030306 microbiology, MESH: Polymerase Chain Reaction, Pneumonia, biology.organism_classification, medicine.disease, Kidney Transplantation, MESH: Male, MESH: Tissue Fixation, Tomography, X-Ray Computed, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Immunocompromised patients who develop invasive filamentous mycotic infections can be efficiently treated if rapid identification of the causative fungus is obtained. We report a case of fatal necrotic pneumonia caused by combined pulmonary invasive mucormycosis and aspergillosis in a 66 year-old renal transplant recipient. Aspergillus was first identified during the course of the disease by cytological examination and culture (A. fumigatus) of bronchoalveolar fluid. Hyphae of Mucorales (Rhizopus microsporus) were subsequently identified by culture of a tissue specimen taken from the left inferior pulmonary lobe, which was surgically resected two days before the patient died. Histological analysis of the lung parenchyma showed the association of two different filamentous mycoses for which the morphological features were evocative of aspergillosis and mucormycosis. However, the definitive identification of the associative infection was made by polymerase chain reaction (PCR) performed on deparaffinized tissue sections using specific primers for aspergillosis and mucormycosis. This case demonstrates that discrepancies between histological, cytological and mycological analyses can occur in cases of combined mycotic infection. In this regard, it shows that PCR on selected paraffin blocks is a very powerful method for making or confirming the association of different filamentous mycoses and that this method should be made available to pathology laboratories.

Published
2010
Full Text
View/download PDF

6. Expression analysis of murine genes using in situ hybridization with radioactive and nonradioactively labeled RNA probes

Author

Anne, Chotteau-Lelièvre, Pascal, Dollé, Françoise, Gofflot, Institut de génétique et biologie moléculaire et cellulaire (IGBMC), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Louis Pasteur - Strasbourg I, Toussaint, Jean-Luc, Institut de génétique et biologie moléculaire et cellulaire ( IGBMC ), Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), and Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Gene Expression, MESH: Paraffin Embedding, Gene Expression, MESH : RNA Probes, [ SDV.BBM.BM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, MESH: Histological Techniques, In Vitro Techniques, [SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Sensitivity and Specificity, MESH : Frozen Sections, Mice, MESH: Pregnancy, MESH: In Situ Hybridization, Pregnancy, MESH : Mice, Animals, Frozen Sections, MESH : Female, MESH: Animals, MESH: Mice, In Situ Hybridization, Paraffin Embedding, MESH : Embryo, MESH: Frozen Sections, MESH : Paraffin Embedding, Histological Techniques, MESH: Digoxigenin, MESH: Embryo, MESH : Digoxigenin, MESH : In Situ Hybridization, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, RNA Probes, Embryo, Mammalian, MESH: Sensitivity and Specificity, MESH : Gene Expression, MESH : Pregnancy, Female, MESH : Histological Techniques, MESH: RNA Probes, MESH : Animals, MESH : Sensitivity and Specificity, Digoxigenin, MESH: Female
Abstract

International audience; The term in situ hybridization (ISH) refers to all methods allowing the detection of specific DNA (gene loci) or RNA (gene expression products) sequences, using molecular hybridization (base pairing) of labeled nucleic acid probes to target molecules within "intact" cell populations in tissue sections or whole organisms, cultured cells, or chromosomal spreads. For more than two decades, ISH has been one of the main approaches used to characterize gene expression patterns in all laboratory animal models, especially in the context of embryonic development, as well as in human tissue or cell samples for both research and diagnostic purposes. Here, we describe several ISH protocols applied to the analysis of mouse embryos and tissues; this organism has become a reference for mammalian experimental genetics. These protocols use in vitro transcribed RNAs as probes for detection. Radiolabeled probes (using 35S as a radioisotope) allow sensitive ISH on sections of paraffin-embedded material, whereas nonradioactively (digoxigenin) labeled probes can be used both for hybridization of whole embryos (whole-mount ISH) and frozen tissue sections.

Published
2006

7. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

Author

Odile Mondesert, Philip G. Kasprzyk, Olivier Lavergne, Gregoire Prevost, Muriel Quaranta, Marie-Christine Brezak, Pierrïck Auvray, Bernard Ducommun, Marie-Odile Contour-Galcera, Institut Henri Beaufour (IPSEN), IPSEN-BEAUFOUR, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre de Biologie Intégrative (CBI), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Biomeasure, and Milford

Subjects
Cancer Research, MESH: Muscles, MESH: Paraffin Embedding, Administration, Oral, MESH: NADH Tetrazolium Reductase, MESH: Benzoquinones, HeLa, Mice, 0302 clinical medicine, MESH: cdc25 Phosphatases, Benzoquinones, MESH: Animals, Enzyme Inhibitors, MESH: Biological Availability, 0303 health sciences, biology, Kinase, Cell cycle, MESH: Drug Resistance, Neoplasm, 3. Good health, Cell biology, MESH: Schizosaccharomyces, Oncology, MESH: Enzyme Inhibitors, 030220 oncology & carcinogenesis, MESH: Administration, Oral, Female, MESH: Pancreatic Neoplasms, biological phenomena, cell phenomena, and immunity, CDC25A, MESH: Xenograft Model Antitumor Assays, MESH: Rats, Cdc25, Transplantation, Heterologous, Biological Availability, Mice, Nude, Mitosis, MESH: Thiazoles, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, 03 medical and health sciences, In vivo, MESH: Cell Proliferation, Schizosaccharomyces, MESH: Mice, Nude, Animals, Humans, cdc25 Phosphatases, MESH: Mice, MESH: Transplantation, Heterologous, Cell Proliferation, 030304 developmental biology, MESH: Humans, Cell growth, MESH: Mitosis, biology.organism_classification, Xenograft Model Antitumor Assays, MESH: Succinate Dehydrogenase, Pancreatic Neoplasms, MESH: Hela Cells, Thiazoles, enzymes and coenzymes (carbohydrates), Drug Resistance, Neoplasm, Cell culture, biology.protein, Cancer research, MESH: Tissue Fixation, MESH: Female, HeLa Cells
Abstract

Cell cycle regulators, such as the CDC25 phosphatases, are potential targets for the development of new anticancer drugs. Here we report the identification and the characterization of BN82685, a quinone-based CDC25 inhibitor that is active in vitro and in vivo. BN82685 inhibits recombinant CDC25A, B, and C phosphatases in vitro. It inhibits the growth of human tumor cell lines with an IC50 in the submicromolar range, independently of their resistance to chemotherapeutic agents. This inhibitory effect is irreversible on both the purified CDC25 enzyme in vitro and on tumor cell proliferation. The specificity of BN82685 towards the CDC25 phosphatases is shown by an increase in cyclin-dependent kinase 1 tyrosine 15 phosphorylation, by the reversion of the mitosis-inducing effect of CDC25B overexpression in HeLa cells, and by the lack of a growth inhibitory effect in an assay based on the use of a CDC25-independent fission yeast model. Finally, when administered p.o., BN82685 is shown to inhibit the growth of the human pancreatic tumor Mia PaCa-2 xenografted in athymic nude mice. BN82685 is therefore a promising new compound targeting CDC25, which confirms the interest of the inhibition of these enzymes as an anticancer therapeutic strategy.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results